Patents by Inventor Daniel Lee Baker
Daniel Lee Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240140709Abstract: Automated cold storage unit and systems for storing, monitoring, and maintaining a supply of temperature sensitive pharmaceutical and/or other products in compliance with regulatory requirements are provided. Such units contain an array of independently addressable holding locations for containers with product in one or more controlled temperature zones fitted with temperature sensors. The units include a reader to track product information and status. Product movement within the unit is performed by a computer-controlled robot. A user interface device, preferably in communication with an application service provider to provide remotely managed inventory management and other services, provides users with secure access to the contents of the unit and associated product data and information.Type: ApplicationFiled: September 11, 2023Publication date: May 2, 2024Applicant: TruMed Systems, Inc.Inventors: Robert James MANNING, Eugene Abraham BAKER, Kevin Lee BOKELMAN, Daniel KLINE, George M. WOHLHIETER, Anthony David BARGHINI, Wesly Hardin BILLMAN, Dan J. DULL, Nicholas James SNYDER, Mark MAJETTE
-
Publication number: 20220218636Abstract: Compositions and methods for using cyclopropanated structural analogs of fatty acid biofilm dispersal agents are characterized by superior biofilm dispersion. When used in combination with antimicrobials, these analogs decrease the minimum inhibitory concentration of antimicrobial agents required for eradication of the biofilm and/or treatment of infection. Methods for using these analogs include direct application to a surface, blending with lipid based carriers, or covalent anchoring the molecule to a surface. Typically, the cyclopropanated structural analog has the structure according to formula (I): wherein R1 is a C1-C24 linear or branched alkyl group; or an acid halide or acid anhydride thereof.Type: ApplicationFiled: March 23, 2022Publication date: July 14, 2022Applicant: The University of Memphis Research FoundationInventors: Jessica Amber JENNINGS, Daniel Lee BAKER, Rukhsana AWAIS, Zoe HARRISON, Babatunde RAJI
-
Patent number: 11311506Abstract: Compositions and methods for using cyclopropanated structural analogs of fatty acid biofilm dispersal agents are characterized by superior biofilm dispersion. When used in combination with antimicrobials, these analogs decrease the minimum inhibitory concentration of antimicrobial agents required for eradication of the biofilm and/or treatment of infection. Methods for using these analogs include direct application to a surface, blending with lipid based carriers, or covalent anchoring the molecule to a surface. Typically, the cyclopropanated structural analog has the structure according to formula (I): wherein R1 is a C1-C24 linear or branched alkyl group; or an acid halide or acid anhydride thereof.Type: GrantFiled: October 31, 2019Date of Patent: April 26, 2022Assignee: THE UNIVERSITY OF MEMPHIS RESEARCH FOUNDATIONInventors: Jessica Amber Jennings, Daniel Lee Baker, Rukhsana Awais, Zoe Harrison, Babatunde Raji
-
Publication number: 20200138753Abstract: Compositions and methods for using cyclopropanated structural analogs of fatty acid biofilm dispersal agents are characterized by superior biofilm dispersion. When used in combination with antimicrobials, these analogs decrease the minimum inhibitory concentration of antimicrobial agents required for eradication of the biofilm and/or treatment of infection. Methods for using these analogs include direct application to a surface, blending with lipid based carriers, or covalent anchoring the molecule to a surface.Type: ApplicationFiled: October 31, 2019Publication date: May 7, 2020Applicant: THE UNIVERSITY OF MEMPHIS RESEARCH FOUNDATIONInventors: Jessica Amber Jennings, Daniel Lee Baker, Rukhsana Awais, Zoe Harrison, Babatunde Raji
-
Patent number: 8969590Abstract: Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include thioureas, diphenyldiazerenes, xanthenes, and isoindoles and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.Type: GrantFiled: September 18, 2012Date of Patent: March 3, 2015Inventors: Abby Louise Parrill-Baker, Daniel Lee Baker
-
Patent number: 8497371Abstract: Novel and optimized classes of pipemidic acid derivative compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes of compounds exhibit exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.Type: GrantFiled: October 26, 2010Date of Patent: July 30, 2013Assignee: University of Memphis Research FoundationInventors: Abby Louise Parrill-Baker, Daniel Lee Baker, Adrienne Hoeglund
-
Patent number: 8343934Abstract: Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include naphthalenesulfones, phenylsulfones, and certain peptides with unnatural amino acids and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.Type: GrantFiled: June 30, 2010Date of Patent: January 1, 2013Assignee: University of MemphisInventors: Abby Louise Parrill-Baker, Daniel Lee Baker, Elton Jeffrey North
-
Patent number: 8268891Abstract: Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include thioureas, diphenyldiazerenes, xanthenes, and isoindoles and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.Type: GrantFiled: November 13, 2008Date of Patent: September 18, 2012Assignee: University of Memphis Research FoundationInventors: Abby Louise Parrill-Baker, Daniel Lee Baker
-
Publication number: 20120100592Abstract: Novel and optimized classes of pipemidic acid derivative compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes of compounds exhibit exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.Type: ApplicationFiled: October 26, 2010Publication date: April 26, 2012Inventors: Abby Louise Parrill-Baker, Daniel Lee Baker, Adrienne Hoeglund
-
Patent number: 8022239Abstract: A novel class of compounds to inactivate autotaxin enzymes is provided. Such compounds include mono- and di-fluoromethylphenyl C12-C18 phosphodiesters and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds are non-cytotoxic, and can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of producing such novel compounds are encompassed within this invention as well as methods of inactivating autotaxin to certain degrees therewith.Type: GrantFiled: October 2, 2009Date of Patent: September 20, 2011Assignee: The University of Memphis Research FoundationInventors: Abby Louise Parrill-Baker, Daniel Lee Baker, Louis Edward Montedonico
-
Publication number: 20110160148Abstract: Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include naphthalenesulfones, phenylsulfones, and certain peptides with unnatural amino acids and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.Type: ApplicationFiled: June 30, 2010Publication date: June 30, 2011Applicant: THE UNIVERSITY OF MEMPHIS RESEARCH FOUNDATIONInventors: Abby Louise Parrill-Baker, Daniel Lee Baker, Elton Jeffrey North
-
Publication number: 20100136650Abstract: A novel class of compounds to inactivate autotaxin enzymes is provided. Such compounds include mono- and di-fluoromethylphenyl C12-C18 phosphodiesters and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds are non-cytotoxic, and can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of producing such novel compounds are encompassed within this invention as well as methods of inactivating autotaxin to certain degrees therewith.Type: ApplicationFiled: October 2, 2009Publication date: June 3, 2010Inventors: Abby Louise Parrill-Baker, Daniel Lee Baker, Louis Edward Montedonico